Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:18 2024-04-26 am EDT 5-day change 1st Jan Change
2.85 GBX 0.00% Intraday chart for Allergy Therapeutics plc +7.55% +14.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58 MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024 CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Allergy Therapeutics starts dosing patients in peanut allergy trial AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors CI
Allergy Therapeutics forecasts revenue drop but trials going well AN
Alliance Pharma appoints chair; FireAngel sales down AN
Scancell's Chief Development Officer to Step Down MT
Allergy Therapeutics resumes trading on AIM; annual revenue plunges AN
Allergy Therapeutics amends facility, plans warrant issue AN
Allergy Therapeutics Agrees Amendment to Loan Facility MT
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens AN
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial MT
Allergy Therapeutics shares jump as hails grass allergy jab data AN
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer AN
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL CI
Allergy Therapeutics in Advanced Talks for Potential Funding; Shares Drop MT
AIM WINNERS & LOSERS: Synectics to beat forecast; Dekel shares jump AN
Allergy Therapeutics stock falls on lower sales outlook AN
Chart Allergy Therapeutics plc
More charts
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
More about the company
  1. Stock Market
  2. Equities
  3. AGY Stock
  4. News Allergy Therapeutics plc
  5. Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M